Bronchiectasis Therapeutic Market Trends

Growth Drivers

• High prevalence and complex management of Nontuberculous Mycobacterial (NTM) infections: The bronchiectasis therapeutic market continues to grow from the increasing incidence of nontuberculous mycobacteria (NTM) infections in bronchiectasis patients. According to a report by NLM in December 2023, 37.9% of the patients recorded in the U.S. Bronchiectasis and NTM Research Registry were impacted during the last few years. The report has also highlighted that delayed treatment initiation, especially for Mycobacterium avium complex (MAC) infections, underscores the urgent need for improved diagnostics and targeted therapies. These drive the expansion and innovation of therapeutic options for enhanced management of the disease.
• Growing comorbidity with chronic respiratory diseases: Increasingly common long-term lung conditions, including COPD, asthma, and non-tuberculous mycobacterial (NTM) infections, help to drive the need for bronchiectasis treatment in the bronchiectasis therapeutics market. These conditions tend to worsen the disease and increase the healthcare costs, which creates a demand for better long-term treatment solutions. As per a report by NLM in October 2024, the average age of bronchiectasis patients in the US grew from 61 to 68 years, also growing from 64.2 to 67.6 years in Germany. There is now a greater need to address the combined respiratory issues with integrated care approaches, which is being responded to by healthcare facilities globally.
• Advancements in therapeutic technologies and personalized medicine:
  The bronchiectasis therapeutics market continues to expand and evolve due to new therapies, such as inhaled antibiotics, targeted biologics, and other drug delivery systems. These therapies allow for less invasive and more precise treatment, and they also decrease the side effects and increase the chances that more patients are getting treatment. Clinical outcomes are also improving due to personalized medicine approaches, which customize treatment to the microbiology and genetic profiles of each patient.  These developments are increasing the scope of treatments while fostering further investment in research and development of bronchiectasis.

Exporters and Importers Trend in Market

Exporters And Importers of Therapeutic Respiration Apparatus in 2023

Source: OEC, August 2025

Challenges

• Complexity of disease management: Managing the bronchiectasis therapeutic market is inherently challenging due to the heterogeneous nature and frequent coexistence with other respiratory conditions of this disease. Treatment often requires a multifaceted approach involving long-term antibiotics, airway clearance techniques, and management of exacerbations, which can be a burden for patients and healthcare systems. The lack of standardized treatment protocols and variability in disease severity complicate clinical decision-making, leading to inconsistent outcomes and difficulties in optimizing therapy across diverse patient populations.

• Limited access to specialized therapies: Availability of bronchiectasis-targeted treatments is still an important hurdle, especially in underprivileged or rural communities where there may be limited access to specialist pulmonologists and high-end diagnostics. Moreover, treatment options, such as inhaled antibiotics and airway clearance devices, may be expensive. This limits the ability of patients to fully comply with the treatment regimen and to initiate treatment on time. As a result, the management of the condition is sub-optimal, increasing the chances of exacerbations and hospitalizations. Access to treatment for bronchiectasis patients is critical for improving long-term patient outcomes.